July 2021

Announcing additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients

Read more

April 2020

BIOSTOCK: Synact Pharma on expansion into Covid-19 (also available in Swedish)

English: Swedish: Read more

October 2019

Redeye: Adding an indication

We had the opportunity to dig deeper in to the commercial potential for AP1189 in nephrotic syndrome. As a result, we raise our base case valuation to SEK 17 per share.   Read more

January 2017

SynAct presented in Copenhagen at Sedermera Investor Event

On 27 January 2017 Synact Pharma presented the company at the Sederemera event in Copenhagen. Read more